Sildenafil Citrate
Brand names: Sildenafil Citrate, Viagra, Revatio
At a glance
- Medicare prescriptions, 2024
- 505,610
- Medicare drug cost
- $26.1M
- Average cost per prescription
- $51.54
- Clinicians who prescribed it
- 19,752
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Adults REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.
From the FDA-approved prescribing information (label dated January 2023). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 27.5%
- Internal Medicine 26.9%
- Nurse Practitioners 11.3%
- Urology 10.4%
- General Practice 5.6%
- Pulmonology 5.2%
- Physician Assistants 3.6%
- Cardiology 3.2%
- Heart Failure & Transplant Cardiology 1.4%
- Critical Care Medicine 0.9%
- Geriatric Medicine 0.8%
- Rheumatology 0.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 87% from 2019 to 2024.
Biggest change by state since 2019
- Illinois +511%
- New York +327%
- Pennsylvania +198%
- Texas +194%
- North Carolina +187%
- Florida (smallest change) −6%
- Puerto Rico (smallest change) +96%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Aphena Pharma Solutions - Tennessee, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | blue capsule, 16 mm | 1A1 |
Nivagen Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | blue round tablet, 7 mm | 25 SL |
| 50 mg | blue capsule, 13 mm | 1A2 |
| 100 mg | blue capsule, 16 mm | 1A1 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | blue capsule, 13 mm | 1A2 |
Pfizer Laboratories Div Pfizer Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | white round tablet, 7 mm | PFIZER RVT20 |
Viatris Specialty LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | white round tablet, 7 mm | RVT 20 VLE |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $3,000 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Mylan Inc. $3,000
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.